Corrigendum to “Mixed methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) trial” [Resuscitation Plus 6 (2021) 100131]

The authors regret to inform that we have identified a computational error in our recent publication, “Mixed methods feasibility study for the Surviving Opioid Overdose with Naloxone Education and Resuscitation (SOONER) Trial”.

This error was identified in the process of preparing another manuscript arising from the same study, which used similar statistical coding. In brief, our statistical team identified that there was a coding error in R involving the labelling of categorical variables. The issue has now been corrected.

Our clinical trials unit has responded to this error by initiating a thorough investigation and quality assurance process including a root-cause analysis to determine how this occurred and ensure that this kind of error does not recur. In addition, all other analyses and reported statistics in this paper have been reviewed by an independent senior statistician to ensure that they are correct.

The error identified affects Table 2 and Table 3 of the published manuscript. Revised versions of these tables are appended below.

Table 2.

Participant Demographics [CORRECTED].

Category	Overall N = 30
Age (median [IQR])	40.5 [33.0–53.2]
Self-reported gender no. (%)
Female	10 (33.3)
Male	18 (60.0)
Other	2 (6.7)
Born in Canada no. (%)	25 (83.3)
Self-reported ethnicity/race no. (%)
Indigenous	4 (13.3)
White	21 (70.0)
Othera	5 (16.7)
Housing n (%)
Homeless/on street	3 (10.0)
Renting	12 (40.0)
Shelter/Hostel	6 (20.0)
Otherb	9 (30.0)
Education n (%)
Elementary	8 (26.7)
High School	8 (26.7)
University/College	12 (40.0)
Graduate/Professional	2 (6.7)
Previous first aid, CPR or OEND training	18 (62.1)
Previously witnessed overdose	16 (61.5)

^aCategories “other”, “mixed heritage”, “Asian — South”, “Black-African”, “Black-Carribean”, “Black —North American”, and “Latin American” collapsed to protect small cell sizes.

^bCategories “other”, “supportive housing” and “own home” collapsed to protect small cell sizes.

Table 3.

Opioid Use Information Among People who Use Opioids (N = 16) [CORRECTED].

Group	Feasibility (N = 30)
Participants who take prescription opioids	14
Methadone or buprenorphine (%)a	10 (71.4)
Morphine (%)	4 (28.6)
Other (%)a	3 (21.4)
Participants who take non-prescription opioids	11
Fentanyl (%)	10 (90.9)
Heroin (%)	5 (45.5)
Other (%)	4 (36.4)
Injection opioid use (%)	7 (43.8)
Number of opioids used (%)
1	5 (31.2)
1–3	8 (50.0)
4 or more	3 (18.8)
Frequency of opioid use	Non-prescription (N = 11)	Prescription (N = 14)
Multiple times per day	4 (36.4)	4 (28.6)
Every day or most days	3 (27.3)	10 (71.4)
A few times a week	0 (0.0)	0 (0.0)
Rarely or few times a month	4 (36.4)	0 (0.0)

^aCategories collapsed to protect small cell sizes.

The authors would like to apologise for any inconvenience caused.